Assembly Bio ditches hepatitis B drug on liver toxicity concerns in mid-stage test

Bay Area microcap biotech Assembly Bio had big plans for a lead hepatitis B drug, but safety red flags have now led the company to ditch the program altogether. Assembly Bio has discontinued development of ABI-H2158, its candidate to treat hepatitis B, after observing elevated levels of alanine transaminase (ALT)…

...

Click to view original post